Pharmaceutical Products and The Bribery Act June 2011

more+
less-

The Bribery Act came into force on 1 July 2011. It has attracted much controversy, and because of its jurisdictional reach beyond the borders of the UK, it has given rise to concern in various industries including the pharmaceutical industry and in particular in the areas of hospitality, gifts and other inducements to healthcare professionals.

It is therefore welcome that the Association of the British Pharmaceutical Industry’s (ABPI) and the Prescription Medicines Code of Practice Authority (PMCPA) have agreed with the Serious Fraud Office (SFO) to develop a Memorandum of Understanding (MOU) providing clarification about the enforcement for breaches of the ABPI Code in cases where a breach of the Code is also a potential breach of the Act.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Antitrust & Trade Regulation Updates, Criminal Law Updates, International Trade Updates, Business Torts Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Stuart Miller | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »